Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy
German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...
Chipscreen Biosciences’ CS12088 Gets NMPA Clearance for Hepatitis B Study
China-based Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that the National Medical Products Administration...
Hengrui Pharmaceuticals Gets NMPA Green Light for SHR-A2009 Study
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that the National Medical Products Administration...
GE Healthcare’s China CEO Yihao Zhang to Retire, Will Song Named Successor
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced the...
Zhongsheng Pharmaceutical’s RAY1225 Gets Green Light for Phase III Study
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) announced that it has received approval in...
Akeso Inc. Completes Patient Enrollment for AK138D1 Phase I Study
China-based biotech Akeso Inc. (HKG: 9926) announced the completion of patient enrollment in the Phase...
CARsgen Therapeutics Administers KJ-C2219 in SLE Patient in IIT
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that it has administered its KJ-C2219 at...
Adagene Starts Phase II Trial of Muzastotug for Colorectal Cancer
China-based Adagene Inc. (NASDAQ: ADAG) announced the initiation of an Investigator-Initiated (IIT) Phase II trial...
Shanghai Moyang Biotech’s Aphranel CC Needle Wins NMPA Approval
China-based Shanghai Moyang Biotechnology Co., Ltd, an innovation-focused company in nanomedical biomaterials and Class III...
Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...
EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases
EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to...
AstraZeneca’s Camizestrant Shows Promise in SERENA-6 Breast Cancer Study
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) announced positive interim analysis results from the Phase III...
Bayer’s Gadoquatrane Shows Positive Results in Phase III QUANTI CNS Study
German pharmaceutical giant Bayer (ETR: BAYN) announced positive results from the Phase III QUANTI CNS...
Ping An Good Doctor Launches AI-Powered Digital Doctor Service
China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as Ping An...
Eli Lilly to Establish Four New US Pharma Manufacturing Sites
US major Eli Lilly & Co. (NYSE: LLY) announced plans to establish four new pharmaceutical...
Precigen’s RRP Therapy PRGN-2012 Gets FDA Review
US-based cell and gene therapy (CGT) specialist Precigen, Inc. (NASDAQ: PGEN) announced that the US...
Burning Rock and MGI Tech Partner to Advance Oncology Precision Medicine
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has entered into a strategic partnership with...
Cell Store and Cygenta Forge Strategic Alliance in Cell and Gene Therapy Field
Beijing-based biotech firms Cell Store, a biological sample cryopreservation technology platform, and Cygenta, a Contract...
InnoCare Pharma’s Orelabrutinib Shows Efficacy in RRMS at ACTRIMS Forum
Beijing-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the presentation of Phase II study results...
Jiangsu Hengrui’s HRS-1301 Receives NMPA Approval for Hyperlipidemia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that its Category 1 chemical drug...